Vistin Pharma ASA - Asset Resilience Ratio
Vistin Pharma ASA (VISTN) has an Asset Resilience Ratio of 3.08% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Vistin Pharma ASA balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Vistin Pharma ASA's Asset Resilience Ratio has changed over time. See VISTN book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vistin Pharma ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VISTN market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr12.67 Million | 3.08% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr12.67 Million | 3.08% |
Asset Resilience Insights
- Limited Liquidity: Vistin Pharma ASA maintains only 3.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Vistin Pharma ASA Industry Peers by Asset Resilience Ratio
Compare Vistin Pharma ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Vistin Pharma ASA (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Vistin Pharma ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 6.50% | Nkr26.20 Million ≈ $2.76 Million |
Nkr403.40 Million ≈ $42.45 Million |
+6.14pp |
| 2022-12-31 | 0.35% | Nkr1.44 Million ≈ $151.00K |
Nkr407.21 Million ≈ $42.85 Million |
-23.58pp |
| 2020-12-31 | 23.93% | Nkr77.04 Million ≈ $8.11 Million |
Nkr321.92 Million ≈ $33.87 Million |
-12.75pp |
| 2019-12-31 | 36.68% | Nkr184.91 Million ≈ $19.46 Million |
Nkr504.17 Million ≈ $53.05 Million |
-10.03pp |
| 2018-12-31 | 46.71% | Nkr233.58 Million ≈ $24.58 Million |
Nkr500.06 Million ≈ $52.62 Million |
+14.71pp |
| 2016-12-31 | 32.00% | Nkr89.44 Million ≈ $9.41 Million |
Nkr279.52 Million ≈ $29.41 Million |
-- |
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.